CND Life Sciences Closes $6.32M Debt for Neurodiagnostics

CND Life Sciences has closed a $6.32M debt financing, giving the Scottsdale neurodiagnostics company additional growth capital as it expands the commercial and research footprint of its skin-biopsy testing platform. An amended Form D filed with the SEC on August 3, 2026 shows that CND sold the full $6,316,514 offering to 14 accredited investors. The first sale occurred June 9, and the filing lists $0 remaining, but it does not disclose the investors, interest rate, maturity, valuation, or use of proceeds.

The financing matters because CND is trying to move an evidence-backed neurodiagnostic tool from specialist adoption toward broader clinical and biopharmaceutical use. The company reported completing its 50,000th commercial Syn-One Test in November 2025, while its biomarker technology is also being used in drug-development research.

What Happened

The latest filing establishes that CND raised debt rather than another priced equity round. That distinction shapes what can be said about the deal: the company gained $6.32M in capital without disclosing a new equity valuation, but the cost, covenants, maturity, and lender identities remain private. Any claim about the financing's exact purpose would run beyond the public record.

The August amendment also corrects an incomplete market picture. Several private-company databases still describe the June financing as approximately $4.31M, reflecting an earlier Form D. The amended filing reports $6,316,514 offered and sold, making the SEC record the more current source for the deal amount.

This debt follows a $13.5M Series A equity financing announced in May 2025, including $8.6M in a Series A3 offering. That round named Labcorp, MBX Capital, VILAS Ventures, and a group of existing investors. CND also received a separate $3M NIH Small Business Innovation Research grant in October 2025 for a three-year study examining Parkinson disease risk in people with essential tremor.

Why CND Life Sciences Matters

CND was founded in 2017 by Todd D. Levine, MD, Christopher H. Gibbons, MD, MMSc, and Roy Freeman, MD. The company operates a CLIA-certified, CAP-accredited laboratory in Scottsdale and launched the Syn-One Test commercially in August 2019.

Syn-One analyzes three small skin-biopsy samples for phosphorylated alpha-synuclein in cutaneous nerves. That pathological protein is associated with synucleinopathies including Parkinson disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure. CND positions the test as objective evidence that supports a clinician's evaluation, not as a substitute for clinical judgment.

That distinction is important in a field where symptoms can overlap and diagnosis can take time. A laboratory test has to do more than produce an interesting signal; it has to fit clinical workflows, earn payer confidence, maintain quality across specimens, and show that its information changes care in useful ways.

Evidence Before Expansion

A prospective, blinded study published in JAMA in 2024 evaluated 428 participants across 30 sites, with 343 participants included in the primary analysis. Phosphorylated alpha-synuclein was detected in 92.7% of participants with Parkinson disease, 98.2% with multiple system atrophy, 96.0% with dementia with Lewy bodies, and 100% with pure autonomic failure. The marker was detected in 3.3% of controls.

Those results are encouraging, but the study authors also called for further validation in unselected clinical populations. That caveat should travel with the headline numbers because diagnostic credibility is built by showing where evidence is strong, where it is still developing, and how a test performs outside a tightly characterized study cohort.

CND said it completed its 50,000th Syn-One Test in November 2025. Commercial volume does not settle every clinical question, but it does show that neurologists and patients are engaging with the model at meaningful scale.

A Two-Sided Diagnostics Business

CND is building across both patient care and biopharma research. On the clinical side, Syn-One provides pathology findings intended to support diagnostic evaluation. On the research side, the company's biomarker services and NerValence platform help quantify synuclein pathology and other cutaneous markers in pharmaceutical trials.

That two-sided model creates a useful feedback loop. Clinical adoption can generate operational experience and a larger body of real-world specimens, while trial work can deepen the company's role in measuring disease biology and treatment response. It also creates execution pressure because laboratory quality, evidence generation, reimbursement, commercial education, and pharmaceutical partnerships all have to mature together.

CEO Richard J. Morello is leading that operating challenge. Todd D. Levine remains CMO, Christopher H. Gibbons serves as CSO, and Roy Freeman continues as Senior Scientific Advisor, preserving a direct line between the company's founding science and its commercial strategy.

What the Financing Signals

Debt is neither automatically conservative nor automatically aggressive. For a private diagnostics company, its usefulness depends on the terms, existing cash position, revenue profile, and the speed at which additional investment can produce durable adoption. None of those financing details is disclosed in CND's filing, so the responsible conclusion is narrower: the company secured another $6.32M without announcing a new equity price.

The broader signal is that neurodiagnostics is moving toward measurable biology. Clinical examination remains central, but companies are competing to give clinicians and drug developers more objective ways to identify pathology, stratify patients, and monitor disease. CND's opportunity is to prove that skin-based evidence can become a dependable part of that shift.

The next milestones matter more than the financing headline. Editors and operators should watch for additional clinical-utility data, payer coverage, evidence from the NIH-backed Syn-Q study, growth in biopharma partnerships, and any company disclosure explaining how the new debt will be deployed. Capital creates room to move, but evidence, access, and execution determine whether that room becomes a larger market.